24-week, Post-Marketing Surveillance Analysis of Upadacitinib in Japanese Patients with Rheumatoid Arthritis: The 2024 Interim Report

被引：0

作者：

Fujii, Takao ^{[1
]}

Okamoto, Nami ^{[2
]}

Abe, Asami ^{[3
]}

Takagi, Michiaki ^{[4
]}

Takahashi, Nobunori ^{[5
]}

Nakajima, Atsuo ^{[6
]}

Nakajima, Ayako ^{[7
]}

Nakayamada, Shingo ^{[8
]}

Nishida, Keiichiro ^{[9
]}

Kawaberi, Takeshi ^{[10
]}

Sunaga, Naomi ^{[10
]}

Tsujita, Yuki ^{[11
]}

Chonan, Sumi ^{[12
]}

Kuwana, Masataka ^{[13
]}

Tanaka, Yoshiya ^{[14
]}

机构：

[1] Wakayama Med Univ, Wakayama, Japan

[2] Osaka Rosai Hosp, Sakai, Osaka, Japan

[3] Niigata Rheumat Ctr, Shibata, Japan

[4] Yamagata Univ, Fac Med, Yamagata, Japan

[5] Nagoya Univ, Grad Sch Med, Nagoya, Aichi, Japan

[6] Ueno Dialysis Clin, Tokyo, Japan

[7] Mie Univ Hosp, Ctr Rheumat Dis, Tsu, Mie, Japan

[8] Univ Occupat & Environm Hlth Japan, Dept Internal Med 1, Kitakyushu, Fukuoka, Japan

[9] Okayama Univ, Dept Orthoped Surg, Grad Sch Med Dent & Pharmaceut Sci, Okayama, Japan

[10] Abbvie GK, Minato Ku, Tokyo, Japan

[11] AbbVie, Minato, Tokyo, Japan

[12] Abbvie GK, Tokyo, Japan

[13] Nippon Med Sch, Dept Allergy & Rheumatol, Tokyo, Japan

[14] Univ Occupat & Environm Hlth, Dept Internal Med, Kitakyushu, Fukuoka, Japan

来源：

ARTHRITIS & RHEUMATOLOGY | 2024年 / 76卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

0506

引用

页码：1026 / 1029

页数：4

共 50 条

[1] 24-week, Post-Marketing Surveillance Analysis of Upadacitinib in Japanese Patients with Rheumatoid Arthritis (Encore1)
Atsumi, Tatsuya
Okamoto, Nami
Takahashi, Nobunori
Tamura, Naoto
Nakajima, Atsuo
Nakajima, Ayako
Fujii, Takao
Matsuno, Hiroaki
Kawaberi, Takeshi
Sunaga, Naomi
Tsujita, Yuki
Chonan, Sumi
Kuwana, Masataka
Takagi, Michiaki
ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4281 - 4283
[2] Safety and effectiveness of certolizumab pegol in Japanese patients with rheumatoid arthritis: Results from a 24-week post-marketing surveillance study
Kameda, Hideto
Nishida, Keiichiro
Nanki, Toshihiro
Watanabe, Akira
Oshima, Yukiya
Momohara, Shigeki
MODERN RHEUMATOLOGY, 2023, 33 (03) : 460 - 471
[3] Post-Marketing Surveillance of Tofacitinib in Japanese Patients with Rheumatoid Arthritis: An Interim Report of Safety Data
Mimori, Tsuneyo
Harigai, Masayoshi
Atsumi, Tatsuya
Kuwana, Masataka
Takei, Syuji
Tamura, Naoto
Fujii, Takao
Matsuno, Hiroaki
Momohara, Shigeki
Yamamoto, Kazuhiko
Kokubo, Takeshi
Endo, Yutaka
Sugiyama, Naonobu
Hirose, Tomohiro
Morishima, Yosuke
Yoshii, Noritoshi
ARTHRITIS & RHEUMATOLOGY, 2017, 69
[4] POST-MARKETING SURVEILLANCE OF TOFACITINIB IN JAPANESE PATIENTS WITH RHEUMATOID ARTHRITIS: AN INTERIM REPORT OF SAFETY DATA
Tamura, N.
Kuwana, M.
Atsumi, T.
Takei, S.
Harigai, M.
Fujii, T.
Matsuno, H.
Mimori, T.
Momohara, S.
Yamamoto, K.
Nomura, K.
Endo, Y.
Sugiyama, N.
Hirose, T.
Morishima, Y.
Yoshii, N.
Takagi, M.
ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1408 - 1408
[5] POST-MARKETING SURVEILLANCE OF TOFACITINIB IN JAPANESE PATIENTS WITH RHEUMATOID ARTHRITIS: AN INTERIM REPORT OF SAFETY DATA
Mimori, T.
Harigai, M.
Atsumi, T.
Kuwana, M.
Takei, S.
Tamura, N.
Fuji, T.
Matsuno, H.
Momohara, S.
Yamamoto, K.
Kokubo, T.
Endo, Y.
Sugiyama, N.
Hirose, T.
Morishima, Y.
Yoshii, N.
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1200 - 1201
[6] Safety and effectiveness of baricitinib for rheumatoid arthritis in Japanese clinical practice: 24-week results of all-case post-marketing surveillance
Takagi, Michiaki
Atsumi, Tatsuya
Matsuno, Hiroaki
Tamura, Naoto
Fujii, Takao
Okamoto, Nami
Takahashi, Nobunori
Nakajima, Atsuo
Nakajima, Ayako
Tsujimoto, Naoto
Nishikawa, Atsushi
Ishii, Taeko
Takeuchi, Tsutomu
Kuwana, Masataka
MODERN RHEUMATOLOGY, 2023, 33 (04) : 647 - 656
[7] Safety and effectiveness of sarilumab in Japanese patients with rheumatoid arthritis refractory to previous treatments: An interim analysis of a post-marketing surveillance
Kameda, Hideto
Tasaka, Sadatomo
Takahashi, Toshiya
Suzuki, Katsuhisa
Soeda, Naoki
Tanaka, Yoshiya
MODERN RHEUMATOLOGY, 2024, 34 (03) : 444 - 452
[8] Malignancy in Japanese Patients with Rheumatoid Arthritis Treated with Tofacitinib: Interim Analysis of All-Case Post-Marketing Surveillance
Tamura, Naoto
Kuwana, Masataka
Atsumi, Tatsuya
Takei, Syuji
Harigai, Masayoshi
Fujii, Takao
Matsuno, Hiroaki
Mimori, Tsuneyo
Momohara, Shigeki
Yamamoto, Kazuhiko
Takasaki, Yoshinari
Nomura, Kazuto
Endo, Yutaka
Hirose, Tomohiro
Morishima, Yosuke
Sugiyama, Naonobu
Yoshii, Noritoshi
Takagi, Michiaki
ARTHRITIS & RHEUMATOLOGY, 2018, 70
[9] Safety and effectiveness of 24-week treatment with iguratimod, a new oral disease-modifying antirheumatic drug, for patients with rheumatoid arthritis: interim analysis of a post-marketing surveillance study of 2679 patients in Japan
Mimori, Tsuneyo
Harigai, Masayoshi
Atsumi, Tatsuya
Fujii, Takao
Kuwana, Masataka
Matsuno, Hiroaki
Momohara, Shigeki
Takei, Syuji
Tamura, Naoto
Takasaki, Yoshinari
Ikeuchi, Satoshi
Kushimoto, Satoru
Koike, Takao
MODERN RHEUMATOLOGY, 2017, 27 (05) : 755 - 765
[10] A JAPANESE POST-MARKETING SURVEILLANCE OF REGORAFENIB IN COLORECTAL CANCER PATIENTS: INTERIM REPORT
Satoh, Taroh
Yamazaki, Naoya
Takikawa, Hajime
Ito, Hideyuki
Ito, Yuichiro
Sakaguchi, Toshiaki
Yamada, Takashi
Muro, Kei
Sugihara, Kenichi
ANNALS OF ONCOLOGY, 2014, 25

← 1 2 3 4 5 →